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Angiogenesis is a pivotal process for growth, 
invasion, and spread of tumors and is therefore 
used as a therapeutic target in many types of 
cancer (Hanahan and Folkman, 1996; Ferrara 
and Kerbel, 2005). Sprouting of capillaries from 
preexisting blood vessels is accomplished by a 
hypoxia-driven mechanism, within which vas-
cular endothelial growth factor (VEGF) A has 
been identified as the most potent inducer of 
the angiogenic cascade (Neufeld et al., 1999). 
Several strategies against VEGF-A (Siemeister 
et al., 1998; W. Leenders et al., 2002; Ferrara 
et  al.,  2004)  or  its  receptor,  VEGF  receptor 
(VEGFR) 1 (Flt-1), and its major signaling re-
ceptor, VEGFR-2 (KDR/Flk-1; Kunkel et al.,   
2001; Sweeney et al., 2002), have been de-
veloped including neutralizing humanized an-
tibodies. Another way to efficiently perturb 
VEGF-A signaling is to block the kinase activity 
of VEGFRs by small-molecule inhibitors, such 
as sorafenib, sunitinib, or PTK787/ZK222584 
(PTK/ZK; Hess-Stumpp et al., 2005; Escudier 
et al., 2007; Thomas et al., 2007). VEGF di-
rectly  stimulates  endothelial  cell  proliferation 
and migration, but its role in pericyte biology 
is still unclear and controversial. The interplay 
of  platelet-derived  growth  factor  (PDGF)  B, 
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Angiogenesis is not only dependent on endothelial cell invasion and proliferation, it also 
requires pericyte coverage of vascular sprouts for stabilization of vascular walls. Clinical 
efficacy of angiogenesis inhibitors targeting the vascular endothelial growth factor (VEGF) 
signaling pathway is still limited to date. We hypothesized that the level of vessel matura-
tion is critically involved in the response to antiangiogenic therapies. To test this hypoth-
esis, we evaluated the vascular network in spontaneously developing melanomas of MT/ret 
transgenic mice after using PTK787/ZK222584 for anti-VEGF therapy but also analyzed 
human melanoma metastases taken at clinical relapse in patients undergoing adjuvant 
treatment using bevacizumab. Both experimental settings showed that tumor vessels, which 
are resistant to anti-VEGF therapy, are characterized by enhanced vessel diameter and 
normalization of the vascular bed by coverage of mature pericytes and immunoreactivity 
for desmin, NG-2, platelet-derived growth factor receptor , and the late-stage maturity 
marker  smooth muscle actin. Our findings emphasize that the level of mural cell differ-
entiation and stabilization of the vascular wall significantly contribute to the response 
toward antiangiogenic therapy in melanoma. This study may be useful in paving the way 
toward a more rational development of second generation antiangiogenic combination 
therapies and in providing, for the first time, a murine model to study this.
© 2010 Helfrich et al.  This article is distributed under the terms of an Attribu-
tion–Noncommercial–Share Alike–No Mirror Sites license for the first six months 
after the publication date (see http://www.rupress.org/terms). After six months 
it  is  available  under  a  Creative  Commons  License  (Attribution–Noncommer-
cial–Share Alike 3.0 Unported license, as described at http://creativecommons 
.org/licenses/by-nc-sa/3.0/).
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vessel stabilization and crucial factors sensitizing blood vessels 
to anti-VEGF therapy, both in melanoma patients and in the 
corresponding murine tumor model.
RESULTS
Tumor growth and progression in MT/ret transgenic mice occurs 
via high, but also low, angiogenic-active vascularization
For analysis of tumor angiogenesis in a physiological setting, 
we used MT/ret transgenic mice, which spontaneously de-
velop multiple melanoma (Kato et al., 1998) and metastases 
in lymph nodes (100%), spleen (>80%), and lung and brain 
(>10%; Fig. S1 A). Tumor development started after a short 
latency of 2–3 wk in the face and on the back of these mice, 
with up to 100 tumors/mouse (20% ± SD) by the age of 
9–10 wk (unpublished data). Immunohistological analyses re-
vealed morphological analogy to human melanoma (unpub-
lished data) and the expression of tyrosinase, tyrosinase-related 
protein (TRP) 1, and gp-100, which are enzymes, regulating 
the quality and quantity of pigment production in melanocytes 
(Fig. S1 B). Interestingly, detailed studies on tumor vascular 
beds showed two different vascular phenotypes in this tumor 
model (Fig. 1, A and B). One predominant type showed a high 
angiogenic-active phenotype (Fig. 1 A) with a mean microves-
sel density (MVD) of 250/mm2 (Fig. 1 C), in contrast to a sec-
ond type which is characterized by only a few intratumoral 
vessels (Fig. 1 B) and a mean MVD of 40/mm2 (Fig. 1 C) and 
which was subsequently described as low angiogenic tumor. 
Analyzing tumor volume in relation to MVD, it became evi-
dent that the phenotype of the vascular network in MT/ret 
melanoma was dependent on neither tumor volume nor 
tumor location (Fig. 1 C and not depicted). Furthermore, the 
intratumoral vessels of the low angiogenic tumors showed an 
almost 10-fold increase in vessel perimeter in comparison with 
the vessels of the high angiogenic tumor type (Fig. 1 D) and a 
significant increase (P ≤ 0.001) in vessel lumina (not depicted). 
In contrast to high angiogenic tumors, total coverage by endo-
thelial cells in the peritumoral tissue area of low angiogenic-
active tumor nodules was observed (Fig. 1 B, arrowhead).
In addition, lymphatic endothelial cells were detected in a 
high number of tumor septa and peritumoral areas but not in 
intratumoral tissue in both tumor types (Fig. S1 C). Assessment 
of the relative abundance of the vascular bed phenotype per 
mouse showed a mean distribution of 83% high angiogenic to 
17% low angiogenic tumors (Fig. 1 E). However, vessel perfu-
sion did not differ in either tumor type (Fig. 1 F). Assessment 
of vessel–vessel distance in individual nodules revealed a mean 
distance of 41.8 µm (±19.1 µm) in tumors with high-angiogenic 
potential in comparison with 172.2 µm (±57.7 µm) in low 
angiogenic-active tumors (Fig. 1 G), which warrant the deliv-
ery of oxygen and nutrients for growth and progression.
Rapid tumor growth of high angiogenic tumors results  
in increased tumor hypoxia
The observations described in the previous section strongly 
suggest that both vascular beds coexist in parallel in the MT/ret 
transgenic model without the need to switch from the low- to 
which is secreted by endothelial cells, and pericytes, express-
ing PDGF receptor (PDGFR) , is important for mural cell 
recruitment during development (Hellström et al., 1999; 
Armulik et al., 2005; Betsholtz et al., 2005; Carmeliet 2005; 
von Tell et al., 2006; Andrae et al., 2008). The absence of 
pericytes, which play a key role in vascular development, ves-
sel stabilization, maturation, and remodeling, is thought to 
be at least partially responsible for the irregular, tortuous, and 
leaky blood vessels found within tumors (Morikawa et al., 
2002; Abramsson et al., 2003). These later steps of the an-
giogenic cascade are controlled by the PDGFs and angiopoi-
etins (Ang’s; Fiedler and Augustin, 2006; Andrae et al., 2008). 
Ang-2, which is expressed by endothelia cells (Fiedler et al., 
2004), acts as a context-specific antagonist of Ang-1/Tie2 sig-
naling. As such, it destabilizes the quiescent endothelial cell 
layer lining the vessel lumina and increases vascular leakage 
(Carlson et al., 2001) but its effects appear to be contextual 
and dependent on local cytokine milieu (Hanahan 1997), par-
ticularly on the presence of VEGF. The benefits of targeting 
both pericytes and endothelial cells in tumor vessels have been 
shown in several tumor models (Bergers et al., 2003; Erber 
et al., 2004), and receptor tyrosine kinase inhibitors that block 
both VEGFRs and PDGFRs have been shown to be more 
efficacious in combination than in single use (Bergers et al., 
2003; Erber et al., 2004). Although systematic studies have 
provided ample evidence that tumor progression correlates 
with tumor-induced angiogenesis, this issue remains contro-
versial in the case of human cutaneous melanoma (Folkman   
et al., 1989; Fallowfield and Cook, 1991; Ilmonen et al., 1999). 
Neovascularization has been considered to be synonymous 
with directed vessel ingrowth in almost all of these studies, but 
alternative growth factor–independent mechanisms have been 
reported, both experimentally and in human tumors (Paku 
1998). It has been shown for some human cancers, including   
non–small cell lung carcinomas (Pezzella et al., 1997) and   
human glioma (Holash et al., 1999), that tumors in more natural 
settings do not always originate avascularly, particularly when 
they arise within or metastasize to vascularized tissue. In such 
settings, tumor cells have the ability to incorporate (i.e., co-opt) 
host vessels (W.P. Leenders et al., 2002), which has also been 
shown as an important mechanism during development of 
cutaneous melanoma (Döme et al., 2002) and melanoma of 
the brain (Küsters et al., 2002). This leads to the speculation 
that although compounds may be efficient inhibitors of angio-
genesis and tumor growth in angiogenesis-dependent tumors, 
their effects may be limited in growth factor–independent 
tumors using mature vessels. The present study analyzed the 
vascular network and levels of pericyte-mediated vessel matu-
ration in human melanoma metastases and melanomas of a 
corresponding tumor model grown during anti-VEGF ther-
apy. In this paper, first, we identify the spontaneous endog-
enously driven murine melanoma model (MT/ret) as the first 
existing model where VEGF-dependent and independent   
tumor growth occurs in parallel, and, second, we provide strong 
evidence that the level of mural cell differentiation influenc-
ing vessel maturation and pericyte coverage is essential for JEM VOL. 207, March 15, 2010 
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et al., 1998). Therefore, we consequently analyzed the re-
cruitment of mural cells in both vascular phenotypes. NG-2, 
Desmin, and PDGFR- have been established as markers 
of early, i.e., immature, pericytes, whereas  smooth muscle 
actin (SMA) has been reported as a marker of mature mural 
cells including pericytes and smooth muscle cells (Nehls et al., 
1992; Morikawa et al., 2002; Gerhardt and Betsholtz, 2003). 
Intratumoral  microvessels  of  MT/ret  transgenic  melanoma 
were covered by Desmin-positive mural cells without signifi-
cant difference in both vascularization phenotypes (80% in 
high angiogenic vs. 92% in low angiogenic tumors; Fig. 3, 
A and B). A comparable percentage of vessels also expressed 
the early markers NG-2 and PDGFR- (Fig. 3 B). In con-
trast, coverage of intratumoral microvessels by -SMA–positive 
mural cells was significantly higher (P ≤ 0.001) in tumors of 
low vessel density (98%) compared with high angiogenic-active 
tumors (2%; Fig. 3, B and C). In accordance with the matura-
tion defect and partial lack of pericyte coverage, excessive vessel 
leakiness was observed in tumors of high vessel density using 
FITC-conjugated dextran (unpublished data). Alongside the 
the high angiogenic vascular phenotype to grow. To address 
potential differences in the tumor growth kinetic, we mea-
sured tumor volume of individual nodules starting early in life 
with tumor-free mice at weekly intervals over a period of 4 wk 
using flat-panel volume computer tomography (fl-VCT). 
Over the first 3 wk, tumor growth kinetics of high angiogenic-
active tumors were significantly increased (P ≤ 0.001) com-
pared with tumors with low vessel density (Fig. 2 A). This was 
paralleled by increased expression of the proliferation marker 
Ki-67 (Fig. 2 B) and apoptosis indices (not depicted) in high 
angiogenic tumors, associated with increased intratumoral 
hypoxic regions in those tumors (Fig. 2, C and D). The distri-
bution of hypoxic areas within both vascular beds was paral-
leled by detection of glutase-1 (unpublished data).
Lack of pericyte coverage and defects in vessel maturation 
promote neovascularization in angiogenic tumors of MT/ret 
transgenic mice
It has been shown that a plasticity window for remodeling 
neovasculature is defined by pericyte coverage (Benjamin 
Figure 1.  Immunohistological and morphometric analyses of the vascular network in melanoma of MT/ret transgenic mice. (A and B) Repre-
sentative images for immunoperoxidase detection of blood vessels using the endothelial marker CD31 in melanoma of high angiogenic (A) and low  
angiogenic (B) potential (n = 478 tumors of 63 mice, independently performed). Arrowheads indicate peritumoral coverage of endothelial cells in low 
angiogenic tumors. (C) Scatter blot for MVD (in millimeters squared) versus tumor volume (in millimeters cubed) in high and low angiogenic tumors  
(n = 20 tumors/vascular bed of four mice). (D) Quantification of vessel perimeter (in millimeters) for both vascular beds of MT/ret transgenic melanoma  
(n = 500 intratumoral vessels [100 vessels/tumor] of five high angiogenic and 100 intratumoral vessels of nine low angiogenic tumors isolated from two 
mice). (E) Immunohistochemically based distribution analyses for the incidence of high and low angiogenic-active tumors per mouse (in percentage) cal-
culated after isolation of all tumors (n = 478 tumors of five mice). (F) Perfusion analysis (in percentage) of intratumoral vessels was performed after injec-
tion of FITC-conjugated lectin into tumor-bearing mice. Analyzing the number of double-positive lectin- and CD31-positive tumor vessels in comparison 
with CD31 single-stained vessels resulted in calculation of vessel perfusion (n = 100 vessels/vascular phenotype in 10 tumors each of four mice). Injection 
experiments were independently performed in each mouse. (G) Analysis of vessel–vessel distances (in micrometers) in both vascular beds of MT/ret-transgenic 
melanoma (n = 500 intratumoral vessels [100 vessels/tumor] of five high angiogenic and 100 intratumoral vessels of nine low angiogenic tumors of two 
mice). Median values of the experimental groups are indicated by the horizontal lines (D and G). All morphometric analyzes were microscopically quantified 
using CD31-stained tissue sections. Error bars, mean ± SD. Bars, 50 µm.494 Antiangiogenic therapy in melanoma | Helfrich et al.
Reduced levels of proangiogenic factors and their receptors 
in endothelial cells of low-vascularized tumors are 
associated with resistance to anti-VEGF therapy
We and others were able to show that the angiogenic cascade 
of the Ang–Tie system is important for controlling vessel as-
sembly, maturation, and quiescence (Maisonpierre et al., 1997;   
Nasarre et al., 2009). Thus, enhanced expression of Ang-2, 
which is responsible for vessel destabilization and immaturity 
(Carlson et al., 2001), may explain the defective integration 
and the partial loss of pericytes, vessel instability, and leakiness 
immunohistological findings, endothelial cells without or with 
partly developed basal lamina were assessed in high angiogenic 
tumors by electron microscopy (Fig. 3 D). Partly reduced peri-
cyte coverage was observed, and integration of pericytes into 
the basal lamina could not be detected (Fig. 3 D). Based on 
pericyte loss, direct connection of tumor cells to endothelial 
cells was observed (Fig. 3 D). In contrast, nearly all blood ves-
sels of low-vascularized tumors exhibited a well constructed 
basal lamina underlining the endothelial cell layer and intact 
integration of pericytes into the vascular wall (Fig. 3 E).
Figure 2.  Comparative analysis of tumor growth rate, tumor cell proliferation, and induction of hypoxia in MT/ret transgenic mice. (A) Tumor 
growth curve of high and low angiogenic-active melanoma. Tumor volume (in millimeters cubed) of individual nodules was measured weekly over a  
period of 4 wk in mice of concordant sex and age using fl-VCT (n = 10 tumors/mouse). The experiment was independently performed three times using 
five mice (***, P ≤ 0.001). (B) Immunofluorescence labeling of tumor cell proliferation using double staining of the proliferation marker Ki-67 (red) and the 
endothelial marker CD31 (green) in tumors of high and low angiogenic potential (n = 15 tumors/vascular phenotype of five mice, analyzed in five sepa-
rate experiments). (C) Immunohistochemical assessment of hypoxic areas in high and low angiogenic-active tumors using pimonidazole injection (n = 10 
tumors/vascular bed of three mice). Filled arrowheads indicate selection of hypoxic tumor cells, empty arrowheads show tumor vessels, the double-
headed arrow indicates the hypoxic-free tumor margin, and the star indicates tumor septa. Injection experiments were independently performed three 
times with the corresponding outcome. (D) Quantification of hypoxic area per tumor (in percentage) in high and low angiogenic-active tumors (n = 10 
tumors/vascular bed of three mice) of three independent experiments; ***, P ≤ 0.001. Representative images are presented (B and C). Error bars, mean ± 
SD. Bars, 100 µm.JEM VOL. 207, March 15, 2010 
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Figure 3.  Quantitative assessment of mural cell maturation and stabilization in MT/ret melanoma. (A and C) Immunohistochemical double 
staining for the endothelial marker CD31 (green) and the early pericytic marker Desmin (red) in low-vascularized (I) and high-vascularized (II) tumors  
(A), as well as for the late differentiation marker -SMA (C; red). Representative images of >10 independently performed experiments are presented (n = 
43 high angiogenic and 27 low angiogenic tumors of four mice). (B) Quantification of vessel coverage, calculated as the percentage of NG-2–, Desmin-, 
PDGFR-–, or -SMA–positive cells compared with the number of CD31-positive vessels (n = 1,087 high angiogenic and 352 low angiogenic tumor ves-
sels of 10 tumors of four mice; ***, P ≤ 0.001). Data are collected from >10 independent experiments. (D and E) Electron microscopic evaluation of the 
vascular wall structure in sections of tumor tissues with high vascular density (two to three blood vessels per microscopic field; D) and low vascular den-
sity (one to two blood vessels in three to four microscopic fields; E), analyzed for their construction of a basal laminar, availability of pericytes, and peri-
cyte integration (n = 9 tumors/vascular bed of three mice). Data are representative of three independent experiments. EC, endothelial cell; Ery, 
erythrocytes within the vessel lumen; TC, tumor cells; star, pericyte; arrowheads, basal lamina. Representative images are presented (A and C–E). Error 
bars, mean ± SD. Bars: (A and C) 100 µm; (D and E) 2 µm.496 Antiangiogenic therapy in melanoma | Helfrich et al.
model because it represents two different vascular beds with 
differences in vessel maturation and stabilization to study 
sensitivity to anti-VEGF therapy. As a reference for an anti-
angiogenic therapy, we used PTK/ZK, a small molecule ty-
rosine kinase inhibitor, which was shown to specifically block 
VEGF-induced autophosphorylation of VEGFR-1, -2, and -3 
and to inhibit endothelial cell proliferation, differentiation, and 
tumor angiogenesis (Wood et al., 2000; Hess-Stumpp et al., 
2005). Oral administration of PTK/ZK in tumor-free MT/ret 
transgenic mice resulted in an excessive reduction (P ≤ 0.001) 
of tumor numbers (Fig. 5, A and B) without affecting the vol-
ume of growing tumors compared with the vehicle-treated 
control group (Fig. 5 C). Histological analyses disclosed that 
nearly all tumors (mean, 98%) that developed during PTK/ZK 
treatment  exhibited  the  low  angiogenic  vascular  phenotype 
(Fig. S2, A and B). As expected, the vehicle-treated control 
group exhibited the normal distribution of 80% high versus 
20% low angiogenic-active tumor beds (Fig. S2 B).
PTK/ZK efficiency represses tumor angiogenesis and results  
in vessel regression
We consequently analyzed the therapeutic effect of anti-VEGF 
therapy using PTK/ZK in tumor-bearing animals to address 
the question of whether PTK/ZK is only able to inhibit endo-
thelial  cell  recruitment  during  sprouting  angiogenesis  or 
whether PTK/ZK is also able to affect intratumoral vasculariza-
tion of existing tumors. For this purpose, tumor-bearing MT/ret 
transgenic mice were selected for a therapeutic intervention 
trial and individually screened for tumor number and volume at 
in high angiogenic tumors, which in turn may result in en-
hanced sensitivity of intratumoral microvessels to anti-VEGF 
therapy.  We  therefore  analyzed  the  expression  of  Ang-1, 
which induces Tie2 activation leading to vessel stabilization 
and maturation (Wong et al., 1997), of its antagonist and ves-
sel destabilization factor Ang-2, of their receptor Tie2, and of 
VEGF-A and its main receptor VEGFR2 in laser microdis-
sected intratumoral endothelial cells by quantitative real-time 
PCR. A significant reduction (P ≤ 0.001) in expression of all 
monitored factors was observed in low angiogenic-active 
endothelial cells, except for levels of Ang-1, which was pres-
ent in equal amounts in both vascular beds. In detail, intra-
tumoral endothelial cells of low angiogenic tumors showed 
an 100-fold decrease in expression of Ang-2 and its recep-
tor Tie2, as well as an 1,000-fold reduction of VEGF-A 
and its major receptor VEGFR2 compared with endothelial 
cells isolated from angiogenic-active vessels (Fig. 4). bEnd3 
cells, a mouse endothelial cell line derived from cortex blood 
vessels, mouse heart, and brain were used as controls for the 
angiogenic factor expression.
PTK/ZK does not affect mature tumor vasculature  
in MT/ret melanoma
Pericytes, in particular, have been recently appreciated as criti-
cal regulators of vessel formation, stabilization, and function 
(Armulik et al., 2005; von Tell et al., 2006), but their role 
in the susceptibility of tumor vasculature to antiangiogenic 
therapy has not been finally clarified. Based on the observa-
tions described in the previous section, we used the MT/ret 
Figure 4.  Logarithmic presentation of quantitative expression analysis of angiogenic factors and corresponding receptors from micro-
dissected endothelial cells of MT/ret melanoma. Laser microdissected intratumoral endothelial cells from cryosections of high and low angiogenic-
active MT/ret melanoma were used for the quantitative real-time PCR analysis of angiogenic factors and their corresponding receptors (n = 5 high and 4 
low angiogenic tumors of three mice). Total RNA of bEND3 cells and mouse brain and heart was used as a control for angiogenic factor expression. The 
analyses for each factor were done in triplicate for each experiment. Three independently performed experiments showed corresponding outcomes. Error 
bars, mean ± SD.JEM VOL. 207, March 15, 2010 
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vessel sleeves in the interspace between CD31-positive endo-
thelial cells (not depicted). Immunohistochemical analyses at 
the end of the therapeutic PTK/ZK treatment showed, again in 
accordance with preventative treatment, that low vascular mel-
anoma nodules did not respond to PTK treatment and there-
fore were distributed as with vehicle-treated mice (Fig. S2 D). 
It has been shown that bone marrow–derived cells could 
also contribute to the resistance to antiangiogenic therapy 
(Bingle et al., 2002; de Visser and Coussens, 2006). Therefore, 
we analyzed the recruitment of macrophages in high and low 
angiogenic tumors treated with vehicle or PTK/ZK during the 
the beginning of therapy, using fl-VCT (Fig. 5 D), and over 
time. In this study, PTK/ZK treatment resulted in inhibition of 
the development of novel tumors compared with vehicle con-
trols (P = 0.005; Fig. 5 E) without affecting the volume of pre-
existing tumor at the end of therapy in both groups (Fig. 5 F). 
In accordance with the prevention study, immunohistological 
analyses revealed that the majority of preexisting tumors showed 
low vascular density at the end of treatment. Interestingly, 
PTK/ZK treatment in preexisting tumors of high angiogenic 
potential obviously resulted in vessel regression (Fig. S2 D), 
which was confirmed by detection of laminin-positive empty 
Figure 5.  Analysis of prevention and therapeutic effects of PTK/ZK on melanoma development and progression in MT/ret transgenic mice. 
(A) Tumor-free mice of concordant age and sex were used for the prevention trial (n = 10 mice/experimental group). MT/ret transgenic mice, orally treated 
with PTK/ZK (50 mg/1 kg in 0.9% NaCl) or vehicle (0.9% NaCl) alone, were visualized at the beginning and end of therapy using fl-VCT. Therapy-resistant 
tumors of the PTK/ZK-treated group are highlighted by empty arrowheads. (B) Quantification of tumor development at the end of the prevention therapy 
in PTK/ZK-treated (n = 9 mice) and vehicle-treated (n = 10 mice) transgenic mice (***, P ≤ 0.001). (C) Total tumor volume analyses (in millimeters cubed) of 
vehicle-treated (n = 100 tumors of 10 mice) and PTK/ZK-treated (n = 73 tumors of nine mice) mice, grown during therapy using fl-VCT. Data of the pre-
vention trial (A–C) were analyzed in two independently performed experiments. (D) Assessment of therapeutic effects of PTK/ZK in tumor-bearing mice 
screened at the beginning and end of therapy by fl-VCT (n = 10 mice/experimental group). Hardly observable tumors are highlighted by empty arrow-
heads. (E) Investigation of tumor number in vehicle- and PTK/ZK-treated mice at the beginning and at the end of therapy (n = 8 mice/experimental group; 
**, P ≤ 0.005). (F) Analyses of total tumor volume (in millimeters cubed) during the therapeutic trial using fl-VCT (n = 100 tumors [beginning and end] of 
four vehicle-treated and five PTK/ZK-treated mice). All data of intervention experiments (D–F) were independently performed twice with corresponding 
outcomes (n = 5 mice/group). Error bars, mean ± SD.498 Antiangiogenic therapy in melanoma | Helfrich et al.
noma metastases observed from patients without therapy, 
bevacizumab-resistant metastases displayed a 17-fold increase 
in the diameter of tumor-associated blood vessels (mean, 5.3 ± 
2.9 vs. 83.3 ± 21.7 µm in untreated patients; P ≤ 0.001; 
Fig. 6 A), as well as an eightfold increase (mean, 305.3 ± 39.8 
vs. 68.9 ± 23.0 µm) in vessel perimeter (P ≤ 0.001; Fig. 6 B). 
Interestingly,  all  blood  vessels  of  bevacizumab-resistant 
tumors, identified by expression of CD31 (Fig. 6 C), exhib-
ited mature vessel morphology by the expression of the early 
differentiation marker Desmin (not depicted) and the late marker 
-SMA (Fig. 6 E) in contrast to the majority of blood vessels 
of  metastases  from  patients  without  bevacizumab  therapy, 
where detection of desmin and -SMA–covered blood vessels 
could not be observed (Fig. 6, D and F).
interventional setting. Immunohistological analyses for F4/80-
expressing macrophages revealed that the majority was located 
inside the lumina of blood vessels or infiltrated as tumor cell–
associated macrophages into the intratumoral areas in both 
tumor phenotypes without significant differences in number or 
localization of vehicle- or PTK/ZK-treated tumors (Fig. S3).
Mature vascular network in human melanoma metastases 
grown during adjuvant bevacizumab therapy
Based on our results using the murine melanoma model, we 
analyzed the vascular network, mural cell recruitment, and level 
of  pericyte  differentiation  in  human  melanoma  metastases, 
which had developed during the UK adjuvant bevacizumab 
trial in stage III cutaneous melanoma. In contrast to mela-
Figure 6.  Immunohistological and morphometric analyses of the vascular network in bevacizumab-resistant human melanoma metastases. 
(A and B) Quantification for vessel diameter (in micrometers; A) or vessel perimeter (in millimeters; B) of all existent tumor-associated blood vessels in 
melanoma metastases of patients receiving bevacizumab therapy (n = 100 vessels in three metastases of three patients), compared with metastases, iso-
lated from patients without therapy (n = 100 vessels in 10 tumors of 10 patients; ***, P ≤ 0.001). (C and D) Immunohistochemical detection of blood  
vessels using the endothelial cell marker CD31 (red) in cutaneous bevacizumab-resistant metastases (C) versus melanoma metastases developed off  
therapy (D). Arrowheads indicate tumor-associated blood vessels for better visualization. (E and F) Analysis of mural cell recruitment using the late stage 
differentiation marker -SMA (brown) in therapy-resistant melanoma (E) and cutaneous metastases developed in patients without treatment (F). Arrow-
heads indicate the blood vessel location of the corresponding tumor section used for CD31 detection (D). Nuclei were counterstained using Hematoxylin. 
All immunohistochemical analyses (C–F) were done using all available and existent melanoma metastases (n = 3 metastases of three patients) of  
patients receiving bevacizumab therapy or melanoma metastases (n = 10 metastases of 10 patients) of patients without therapy. Immunohistological 
detection was performed twice with concordant results. Representative images of analyzed melanoma metastases are presented in C and D. Error bars, 
mean ± SD. Bars, 100 µm.JEM VOL. 207, March 15, 2010 
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or lacking. Consequently, such experiments will need to be 
performed in genetically manipulated models, resembling the 
human situation in aspects of tumor development and angio-
genesis. Conventional mouse melanoma models (e.g., B16), 
based on the transplantation of tumor cells, are not suitable 
for such studies. Transplantation of tumor cells triggers infil-
tration of immune cells such as macrophages, which are known 
to mediate important processes during tumor angiogenesis 
(Hagemann et al., 2009; Shieh et al., 2009), and the natu-
ral situation of tumor development and histology of the 
disease is not comparable with the clinical situation. Now, 
based on our findings, the MT/ret transgenic mouse model 
is the first model which fulfills all criteria of endogenously 
driven spontaneous tumor development and angiogenesis 
and presents, for the first time, VEGF-dependent and -inde-
pendent tumor growth in parallel. Interestingly, distribution 
of both vascular beds does not correlate with tumor volume or 
location. In addition, there was not an experimental hint that 
low angiogenic tumors engage an angiogenic switch during 
progression and metastasis leading to neovascularization and 
vessel destabilization.
The observed altered pattern of mural cell recruitment 
into the vascular wall and the maturation of blood vessels 
in both vascular phenotypes, and their role for susceptibility 
to antiangiogenic therapy, was our most surprising finding. 
However, the mechanisms of Ang-induced mural cell recruit-
ment have not been elucidated. Mechanistically, the most well   
understood pathway of endothelial cell–directed mural cell 
recruitment is through paracrine-acting PDGF-B (Abramsson   
et al., 2003). However, the molecular cross talk between 
the Ang–Tie and PDGF–PDGFR systems has not yet been 
resolved. In previous studies, we were able to show that host-
derived Ang-2 is able to affect early stages of tumor develop-
ment and vessel maturation (Nasarre et al., 2009). Thus, our 
data suggest that hypoxia-triggered up-regulation of Ang-2, 
detected by laser microdissection of tumor-associated endo-
thelial cells of high angiogenic melanoma, resulted in vessel 
destabilization by loss of pericyte coverage, followed by in-
duction of neovascularization. This corresponds with recent 
in vitro observations of hypoxia-regulated Ang-2 expression 
in endothelial cells (Pichiule et al., 2004). These data confirm 
our recent finding that Ang-2 expression levels correlate with 
disease progression and metastasis in sera of melanoma patients 
(Helfrich et al., 2009) and suggests again that the Ang–Tie 
system might have a more direct effect on mural cell recruit-
ment and maturation than previously thought. Interestingly, 
differences in the expression of Ang-1 could not be observed 
between vascular phenotypes. Ang-1 and Ang-2 have been 
described to exert opposing functions during vessel develop-
ment. Although Ang-1–induced Tie2 activation transduces 
survival signals and leads to vessel stabilization and maturation 
(Suri et al., 1996), Ang-2 acts as a vessel destabilizing agent 
that induces permeability and leads to dissociation of cell–cell 
contacts in cultured endothelial cells (Scharpfenecker et al., 
2005). This leads to the speculation that if Ang-2 as an an-
tagonistic Tie2 ligand has a stronger binding capacity for the 
DISCUSSION
In our study, we analyzed human melanoma metastases taken 
at clinical relapse in patients undergoing adjuvant treat-
ment with bevacizumab (AvastinR), but we also analyzed a 
corresponding murine model in which melanomas develop 
spontaneously. In both systems, tumor development during 
anti–VEGF therapy (bevacizumab in humans and PTK/ZK 
in mice) was characterized by a mature intratumoral vascular 
network and stabilization of the vascular wall. The level of 
mural cell differentiation for vessel maturation and the pro-
cess of vessel stabilization by pericyte coverage are believed 
to be major mediators for priming blood vessels to its sensi-
tivity to anti-VEGF therapy.
We also present, for the first time, a murine model (MT/
ret) developing spontaneously metastasizing melanoma char-
acterized by high, but also low, angiogenic-active tumors in 
parallel. This vascular phenotype is independent of tumor 
volume or location. Fast growing highly angiogenic-active 
tumors exhibit hypoxia-driven Ang-2 expression, leading to 
immature intratumoral vascular network, basal lamina de-
fects, and loss of pericytes. In contrast, low angiogenic-active 
tumor nodules displayed stabilized vessels, a slower growth 
kinetic, and increased vessel lumina. Highly vascularized tu-
mors were characterized by significant tumor regression in 
the adjuvant and remodelling of the tumor vascular bed in 
the advanced therapy setting. Interestingly, low angiogenic-
active tumors did not respond to anti-VEGF therapy using 
the small-molecule inhibitor PTK/ZK. Careful expression 
profiling analysis of laser microdissected tumor-associated 
endothelial cells from both vascular beds revealed a significant 
decrease in expression of proangiogenic factors Ang-2 and 
VEGF-A and their receptors Tie2 and VEGFR-2 in VEGF-
resistant MT/ret tumors. In summary, the most prominent 
differences between the two vascular beds observed in this 
melanoma model were the vessel structure (vessel density, 
vessel diameter/perimeter distribution, level of mural cell dif-
ferentiation, and pericyte coverage or basement membrane 
investment) and the expression profile of the vascular-specific 
receptor tyrosine kinase systems.
The concept of antiangiogenic cancer therapy seems sim-
ple at the first look; destroying tumor vasculature and depriv-
ing the tumor of nutrients and oxygen will ultimately induce 
tumor regression. The long-term survival benefit in patients 
of targeting the VEGF signaling pathway has not been so af-
firmative as initially hoped and better clinical outcomes have 
been seen in combination with chemotherapy (Hurwitz et al., 
2004) or additional drugs (Perez et al., 2009). A key finding 
in this context is that VEGF-A/VEGFR-2 blockage leads 
transiently to vessel remodeling and normalization of the 
tumor vascular bed, as described by increased pericyte cover-
age of tumor vessels. This results in vessel stabilization and 
reduced vascular permeability, which facilitates access of 
coadministered chemotherapeutic drugs (Jain 2005).
The role of VEGF in pericyte biology is less clear, and 
experiments aimed at specifically addressing the role of peri-
cytes in responses to antiangiogenic cancer therapies are rare 500 Antiangiogenic therapy in melanoma | Helfrich et al.
Human tumor samples. Melanoma metastases of 59–66-yr-old patients, 
developed between 2 and 8 wk after receiving 8–11 cycles of bevacizumab 
(AvastinR) as adjuvant therapy after resection of AJCC stage IIB, IIC, and III 
cutaneous melanoma, and metastases of patients off therapy (concordant age 
and gender) were assessed for their vascular bed and vessel maturity by 
immunohistochemistry. All available biopsies from patients relapsing on the 
treatment arm of the randomized-controlled clinical phase III study AVAST-M 
(adjuvant aVAStin trial in high-risk melanoma), evaluating the VEGF inhib-
itor bevacizumab, were obtained from October 2008 onward. Informed 
patient consent and the appropriate Institutional Review Board approval was 
obtained for all patients and relapses were confirmed by histological exami-
nation. Human protocols were approved by the Oxford Research Ethics 
Committee C (reference 07/H0606/112, tissue banking) and the trial ap-
proval for AVAST-M (07/Q1606/15).
Immunohistochemistry.  Consecutive  cryosections  (MT/ret  melanoma) 
and paraformaldehyde-fixed paraffin sections (human melanoma metastases) 
were processed for immunostaining. For detection of the endothelial cell 
marker CD31, cryosections were fixed with acetone/methanol (1:1) and endo-
genous peroxidase was blocked with 3% H2O2, followed by avidin/biotin 
blocking. Nonspecific binding was blocked with 5% rabbit serum/1% bovine 
serum albumin in PBS + 0.02% Tween for 30 min. Rat anti–mouse PECAM-1 
(BD), sheep anti–human PECAM-1 (R&D Systems), or ChromPure goat IgG 
(Dianova), used as negative control, were incubated and visualized using DAB 
or AEC Substrate Chromogen system (Dako), followed by counterstaining of 
nuclei using Meyer’s Hemalaun solution (Merck). For the visualization of 
endothelial-pericyte association in MT/ret tumors, double stainings were 
performed using rat anti-CD31 (PECAM-1; BD) combined with rabbit anti-
Desmin antibody (Abcam), rabbit anti-NG2 (Millipore), rat anti-CD140b 
(PDGFR-; eBioscience), or mouse anti–-SMA direct-labeled Cy3 anti-
body (Sigma-Aldrich). Mural cells in human metastases were detected using 
mouse  anti–-SMA  (Sigma-Aldrich)  and  mouse  anti-Desmin  antibody 
(Dako). Cell proliferation was assessed by immunostaining with rat anti–Ki-67 
antibody (clone TEC-3; Dako), basal lamina was visualized by rabbit anti-
laminin (Sigma-Aldrich), and lymphatic endothelial cells were assessed using 
rabbit anti–Lyve-1 (ReliaTech), all of which were counterstained with 
PECAM-1 for vessel detection. Macrophage recruitment was analyzed using 
rat anti-F4/80 antigen (AbD Serotec). The number of macrophages was cal-
culated as F4/80-expressing macrophages per tumor area (in millimeters squared) 
using microscopes (Olympus) and corresponding Cell P Software (Olympus). 
For the detection of expression of the melanogenic enzymes tyrosinase, TRP-
1, and gp-100, paraffin-embedded tumor sections of 8 µm were deparaffinized, 
followed by antigen retrieval using 1 mM EDTA at 90°C for 10 min, blocking 
of nonspecific bindings, and incubation of primary antibodies over night at 
4°C. Antibodies against tyrosinase, TRP-1, and gp-100 were provided by V. 
Hearing (National Institutes of Health, Bethesda, MD). Lymph endothelial 
cells were detected using rabbit anti–Lyve-1 antibody (ReliaTech). Apoptotic 
cells were detected by the MEBSTAIN Apoptosis Kit II (MBL International) 
and quantified as percentage of TUNEL-positive areas per field. Primary anti-
bodies were detected by rabbit anti–rat Alexa Fluor 594, rabbit anti–rat Alexa 
Fluor 488, or donkey anti–rabbit Alexa Fluor 594 (all from Invitrogen). Nuclei 
were counterstained using propidium iodide. Slide fluorescence was examined 
by confocal laser-scanning microscopy (TCS SP2; Leica).
Hypoxic tumor areas were detected by the formation of pimonidazole 
adducts after injection of pimonidazole hydrochloride compound into 
tumor-bearing animals for 30 min. Tumor sections were immunostained using 
the Hypoxyprobe-1 Plus kit according to the manufacturer’s protocol (Nat-
ural Pharmacia International, Inc.). The hypoxic area index was quantified 
as the percentage of positive tumor area per total tumor area in tumors of 
corresponding volume.
Morphometric  analysis  of  tumor  vessels  and  pericyte  coverage. 
Morphogenic analyses of MT/ret tumors were done using consecutive cryo-
sections stained for the endothelial cell marker CD31. The quantification of 
MVD and corresponding tumor volume was calculated using the mean of 
induction of Tie2 activation compared with Ang-1, resulting 
in mural cell depletion and vessel destabilization independent 
of the presence of Ang-1 expression.
Among the most surprising findings of the present study 
was the altered pattern of mural cell recruitment and matura-
tion of blood vessels in human melanoma metastases taken at 
clinical  relapse  in  patients  undergoing  adjuvant  anti-VEGF 
therapy using bevacizumab. These observations were paral-
leled by our corresponding melanoma model using PTK/ZK. 
In both experimental settings tumor vessels, which are resistant 
to anti-VEGF therapy, were characterized by increased vessel 
diameter, normalization of the vascular bed by coverage of 
mature pericytes, and immunoreactivity for Desmin, NG-2, 
PDGFR-, and the late stage maturity marker -SMA. Based 
on the finding that PTK/ZK-resistant blood vessels of MT/ret 
transgenic tumors showed only minor expression of proangio-
genic factors (e.g., Ang-2 and VEGF-A), resulting in low angio-
genic potential and resistance to the traditional antiangiogenic 
approaches, it is highly desirable to identify alternative ways to 
modulate tumor vasculature that do not interfere with the com-
plex regulatory network of proangiogenic factors.
Our findings demonstrate the role of mural cell recruit-
ment and maturation for the susceptibility to anti-VEGF can-
cer therapy. The findings warrant further mechanistic analysis 
to focus on the molecular cross talk between Ang/Tie and 
PDFG/PDGFR signaling during mural cell recruitment and 
maturation. This may contribute to a more rational therapeutic 
exploitation  of  antiangiogenic  therapy  approaches.  In  this 
context, it would be of considerable interest to analyze biopsies 
from patients whose tumors are progressive despite VEGF/
VEGFRs blockage. Results of such studies would lead to 
clinical studies trying to combine modalities targeting tumor 
angiogenesis by inhibition of VEGF signaling and blockage 
of mural cell recruitment, as well as maturity by inhibition of 
PDGF-B pathways. Future work using combination thera-
pies targeting the implicated pathways and analyses of matu-
ration kinetics in spontaneous mouse models will pave the 
way to the rational development of a second generation of 
antiangiogenic combination therapies to overcome the prob-
lem of therapy resistance.
MATERIALS AND METHODS
Mice. Mice (C57BL/6) expressing the human ret proto-oncogene under the 
control of the mouse metallothionein I promoter-enhancer (Kato et al., 1998) 
were provided by M. Kato (Chubu University, Aichi, Japan). MT/ret trans-
genic mice develop spontaneously cutaneous malignant melanoma metasta-
sizing  to  lymph  nodes,  spleen,  lung,  and  brain  that  resemble  human 
melanoma in many aspects of histopathology and clinical development (Kato 
et al., 1998). Mice were crossed with C57BL/6 wild-type mice for hetero-
zygous transgene expression and kept under specific pathogen-free conditions 
in the animal facility of the German Cancer Research Center (Heidelberg, 
Germany) and the Central Animal Laboratory at the University Hospital 
Essen (Essen, Germany). Experiments were performed in accordance with 
government and institute guidelines and regulations. For definition of tumor 
development, mice were monitored for indicated time points using fl-VCT 
(Siemens). Animal procedures were approved by the Regierungspräsidium, 
Karlsruhe, and the Landesamt für Natur, Umwelt und Verbraucherschutz 
Nordrhein-Westfalen, Germany.JEM VOL. 207, March 15, 2010 
Article
501
5-ACACAGGACGGCTTGAAGAT-3; mVEGFR2 forward, 5-TTCT-
GGACTCTCCCTGCCTA-3, and reverse, 5-TCTGTCTGGCTGTC-
ATCTGG-3; mAng-1 forward, 5-AGGCTTGGTTTCTCGTCAGA-3, 
and  reverse,  5-TCTGCACAGTCTCGAAATGG-3;  mAng-2  forward, 
5-CACAGCGAGCAGCTACAGTC-3, and reverse, 5-ATAGCAACC-
GAGCTCTTGGA-3;  and  mTie2  forward,  5-TCTGGGTGGCCAC-
TACCTAC-3, and reverse 5- TGAAAGGCTTTTCCACCATC-3.
Electron microscopy. Electron microscopy was used for the assessment of 
ultrastructural analyses of intratumoral vessels. Tumor samples were isolated 
and divided in half. One half was used for electron microscopy and fixed in 
2.5% glutaraldehyde in 0.1 M cacodylate buffer. The corresponding half was 
used for identification of tumor vascularization by immunohistochemistry. 
Semithin sections from glutaraldehyde-fixed epoxy resin–embedded speci-
mens were stained with paraphenylen diamine for light microscopy (Weis 
and Schröder, 1989). Ultrathin sections of osmium-treated tissue were con-
trast enhanced with lead citrate and uranyl acetate for electron microscopy 
(Weis et al., 1995). The ultrastructure of tumor vessels of both vascular phe-
notypes was studied in ultrathin sections using an electron microscope (902; 
Carl Zeiss, Inc.) equipped with a digital camera. On each section, five to six 
tissue areas were analyzed and used for semiquantitative assessment of vessel 
phenotype in each tumor group.
fl-VCT. For the evaluation of tumor number and volume in the MT/ret 
transgenic mouse line, mice scanning was performed under inhalation narco-
sis, using an fl-VCT scanner (Siemens) at the indicated time points (Kiessling 
et al., 2004; Gupta et al., 2006). Total scan time was 40 s with a rotation time 
of 21 s. A tube voltage of 80 kV and a tube current of 50 mA with continu-
ous radiation were selected. The reconstruction field of view was 4.5 cm 
transaxially with a reconstruction matrix of 512 × 512 pixels and an axial slice 
spacing of 0.2 mm resulting in a voxel size of 0.08 × 0.08 × 0.2 mm3. A 
modestly sharp reconstruction kernel (H80s) was used for image reconstruc-
tion. Image postprocessing was performed using standard three-dimensional 
postprocessing steps, for example, volume rendering. The reconstructed vol-
ume datasets were fitted with a standard DICOM header and transferred to a 
standard radiological postprocessing workstation. The amount of metastasis 
was counted by reviewing the datasets on multiplanar reformations. Standard 
size measurement software was used for the quantification of tumor number 
and volume (InSpace; Siemens). For tumor volume calculation, two orthog-
onal tumor diameters were taken using the virtual caliper tool.
Antiangiogenic  treatment  using  PTK/ZK.  MT/ret  transgenic  mice 
(concordant age and sex per group) were monitored by fl-VCT for the indi-
vidual status of tumor development. Mice were treated at 2 wk of age (pre-
vention, tumor free) or at 4 wk (therapeutic intervention, tumor bearing) by 
oral  administration  of  PTK/ZK  (Novartis;  50  mg/kg  dissolved  in  0.9% 
NaCl) or vehicle (0.9% NaCl) alone, as a control, twice a day over a period of 
4 wk. Mice were measured at the beginning, weekly during treatment, and 
at the end of therapy for assessment of tumor number and volume. At the end 
of therapy, tumors were isolated and analyzed by immunohistochemistry. 
Experimental series (intervention and prevention) were repeated twice.
Statistical analysis. Student’s t test was used for the determination of statis-
tical significance between experimental groups. All results were expressed as 
mean ± SD. P-values <0.05 were considered statistically significant.
Online supplemental material. Fig. S1 shows the characterization of the 
MT7ret mouse model. Fig. S2 analyzes the effects of PTK/ZK on vessel for-
mation in melanoma of MT/ret transgenic mice. Fig. S3 displays the effects 
of PTK/ZK on macrophage recruitment in high and low angiogenic tumors 
of MT/ret melanoma. Online supplemental material is available at http://
www.jem.org/cgi/content/full/jem.20091846/DC1.
We gratefully acknowledge Dr. H.G. Augustin for initial support; K. Leotta for help in 
fl-VCT screening; N. Hochhard and J. Klein for technical assistance; Dr. J. Schenkel, 
three tumor sections per tumor (top, middle, and base) of concordant dis-
tance. MVD was calculated as number of vessels per tumor area. Intratu-
moral vessel perimeter and vessel–vessel distance were measured in tumors 
of high and low vessel density. The percentage of high angiogenic or low 
vascularized tumors per mouse was analyzed by isolation of all tumors per 
mouse followed by endothelial cell detection using immunohistochemistry. 
Pericyte coverage was assessed using the pericyte marker NG-2, Desmin, 
PDGFR-, or -SMA in combination with CD31 for the detection of in-
dividual phases during pericyte differentiation. All vessels per tumor were 
counted using multiple alignment function. For the assessment of pericyte 
coverage in human melanoma metastases, paraffin sections of all available 
bevacizumab-resistant cutaneous metastases and metastases developing off  
therapy were costained for the endothelial cell marker CD31 and pericyte 
markers as described for murine analyses. All present vessels were analyzed 
for vessel perimeter and diameter as described earlier in this section. All 
morphometric analyses were performed on Olympus microscopes and cor-
responding Cell P Software.
Assessment of vessel perfusion and stability. Tumor-bearing MT/ret 
transgenic mice were injected through the tail vein 20 min before killing by 
cervical dislocation using 150 µg FITC-conjugated lectin/150 µl 0.9% NaCl 
from Bandeiraea simplicifolia (Sigma-Aldrich). A perfusion index was quanti-
fied as the percentage of lectin-positive per CD31-positive vessels in high 
and low angiogenic-active tumors. For assessment of vascular stability, mice 
were injected via tail vein using 1 mg/100 µl FITC-conjugated dextran 
(3.000 mol wt). After 15 min of incubation, mice were killed and histologi-
cal analyses were performed.
Laser microdissection of tumor-associated endothelial cells. 10-µm 
cryosections of murine melanoma were cut under RNase-free conditions, 
fixed with 70% ethanol in DEPC, and stained for the identification of 
tumor morphology using Meyer’s Hemalaun solution for 1 min and EosinY 
for 1 s (both Merck). Intratumoral endothelial cells were isolated from five 
high and four low angiogenic tumors using the P.A.L.M. MicroBeam 
Microscope (Carl Zeiss, Inc.). RNA of microdissected endothelial cells was 
isolated using the RNeasy micro kit (QIAGEN) according to the manufac-
turer’s instructions. Expression analysis of dissected tumor-associated endo-
thelial cells was done by quantitative real-time PCR using 1 µg of total 
cellular RNA for reverse transcription.
Quantitative real-time PCR. Specific primers of angiogenic factors and 
their receptors were designed to detect the amounts of various messenger 
RNA species in tumor-associated endothelial cells of the high angiogenic-
active as well as low vascularized melanomas. For the generation of the stan-
dard, each primer pair was subjected to an endpoint PCR in a final volume 
of 30 µl using 1 µl bEND3 complementary DNA (cDNA; for Ang-2, Tie2, 
VEGF, and VEGFR) or BALB/c fibroblast cDNA (for Ang-1) with 0.2 U 
Taq polymerase (GeneCraft), 500 nM dNTP, 3 µl 10× buffer (provided 
by Bio-Rad Laboratories), and 0.5 µM of the particular sense and antisense 
primers under standard conditions (at 95°C for 3 min followed by 34 cycles 
at 95°C for 30 s, 60°C for 45 s, and 72°C for 30 s and an extention at 72°C 
for 8 min). Afterward, the PCR product was purified with PCR purifica-
tion kit and cloned in the pDrive cloning vector with the PCR cloning 
kit (both QIAGEN). Colonies were determined for presence of the insert 
and the DNA was subsequently sequenced. Finally, 1 µl each of cDNA or 
standard DNA within the range of 103 to 108 molecules was amplified with 
SYBR green master mix (Bio-Rad Laboratories) and primers in a final vol-
ume of 25 µl according to the manufacturer’s protocol. The total RNA of 
bEnd3 cells, a mouse endothelial cell line derived from cortex blood vessels 
and mouse heart and brain was isolated using the RNeasy kit (QIAGEN). 
Afterward, 1 µg of each sample was reverse transcribed with the Quanti-
Tect Reverse Transcription kit in a final volume of 20 µl (QIAGEN). The 
following primers were used: mGAPDH forward, 5-TGACCACAGTC-
CATGCCATA-3, and reverse, 5-GACGGACACATTGGGGGTAG-3; 
mVEGF-A forward, 5-ACTGGACCCTGGCTTTACTG-3, and reverse, 502 Antiangiogenic therapy in melanoma | Helfrich et al.
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